Advertisement
MBIO vs MIRM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBIO is a StrongBuy and MIRM is a Hold.
MBIO in +5.73% Uptrend, growing for three consecutive days on November 02, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MBIO advanced for three days, in 147 of 191 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MBIO's RSI Indicator exited the oversold zone, 45 of 59 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on MBIO as a result. In 58 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for MBIO just turned positive on October 27, 2026. Looking at past instances where MBIO's MACD turned positive, the stock continued to rise in 27 of 39 cases over the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 31 of 31 cases where MBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
MBIO broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MBIO entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. MBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.398) is normal, around the industry mean (3.498). P/E Ratio (-0.945) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MIRM in upward trend: 10-day moving average crossed above 50-day moving average on November 09, 2026
The 10-day moving average for MIRM crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on MIRM as a result. In 82 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for MIRM just turned positive on October 12, 2026. Looking at past instances where MIRM's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.
MIRM moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +13.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIRM advanced for three days, in 232 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 220 of 281 cases where MIRM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for MIRM moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 38 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 60 cases where MIRM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIRM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
MIRM broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MIRM's P/B Ratio (-583.904) is very low in comparison to the industry average of (3.498). P/E Ratio (-6.656) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (8.842) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 28 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. MIRM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
MBIO | MIRM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 41 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 28 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 79 | 48 | |
P/E GROWTH RATING 1..100 | 98 | 22 | |
SEASONALITY SCORE 1..100 | 47 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MIRM's Valuation (1) in the null industry is significantly better than the same rating for MBIO (88) in the Pharmaceuticals Major industry. This means that MIRM’s stock grew significantly faster than MBIO’s over the last 12 months.
MIRM's Profit vs Risk Rating (28) in the null industry is significantly better than the same rating for MBIO (100) in the Pharmaceuticals Major industry. This means that MIRM’s stock grew significantly faster than MBIO’s over the last 12 months.
MBIO's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as MIRM (100) in the null industry. This means that MBIO’s stock grew similarly to MIRM’s over the last 12 months.
MIRM's Price Growth Rating (48) in the null industry is in the same range as MBIO (79) in the Pharmaceuticals Major industry. This means that MIRM’s stock grew similarly to MBIO’s over the last 12 months.
MIRM's P/E Growth Rating (22) in the null industry is significantly better than the same rating for MBIO (98) in the Pharmaceuticals Major industry. This means that MIRM’s stock grew significantly faster than MBIO’s over the last 12 months.
| MBIO | MIRM | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 2 days ago 88% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 69% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 73% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 72% | 2 days ago 82% |
| Advances ODDS (%) | 10 days ago 77% | 8 days ago 75% |
| Declines ODDS (%) | 16 days ago 90% | 20 days ago 64% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 69% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 78% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MBIO’s FA Score shows that 0 FA rating(s) are green while MIRM’s FA Score has 3 green FA rating(s).
- MBIO’s FA Score: 0 green, 5 red.
- MIRM’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MBIO’s TA Score shows that 4 TA indicator(s) are bullish while MIRM’s TA Score has 6 bullish TA indicator(s).
- MBIO’s TA Score: 4 bullish, 4 bearish.
- MIRM’s TA Score: 6 bullish, 4 bearish.
Price Growth
MBIO (@Biotechnology) experienced а +10.06% price change this week, while MIRM (@Biotechnology) price change was +8.49% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
MBIO is expected to report earnings on Nov 13, 2026.
MIRM is expected to report earnings on Mar 10, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
MBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, MBIO has been loosely correlated with MDGL. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MBIO jumps, then MDGL could also see price increases.
| Ticker / NAME | Correlation To MBIO | 1D Price Change % | ||
|---|---|---|---|---|
| MBIO | 100% | +15.13% | ||
| MDGL - MBIO | 50% Loosely correlated | -0.04% | ||
| ORMP - MBIO | 44% Loosely correlated | -0.75% | ||
| AXON - MBIO | 40% Loosely correlated | -0.21% | ||
| SCNI - MBIO | 38% Loosely correlated | +7.03% | ||
| MIRM - MBIO | 34% Loosely correlated | +1.33% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SHLD | 61.51 | 0.61 | +1.00% |
| Global X Defense Tech ETF (SHLD) | |||
| JULB | 27.96 | N/A | N/A |
| Aptus July Buffer ETF (JULB) | |||
| DFSE | 43.67 | -0.38 | -0.86% |
| Dimensional Emerging Markets Sustainability Core 1 ETF (DFSE) | |||
| ARVR | 56.52 | -0.51 | -0.90% |
| First Trust Indxx Metaverse ETF (ARVR) | |||
| KGLD | 24.22 | -0.71 | -2.85% |
| Kurv Gold Enhanced Income ETF | |||